The authors concluded that use of an epithelial sodium channel inhibitor combined with hydrochlorothiazide for treatment of hypertension in elderly patients resulted in favourable effects on coronary mortality or sudden cardiac death. The reliability of the conclusions is uncertain given a number of weaknesses in the review methods (risk of error and bias, unclear quality of included studies).
To assess the effect of hydrochlorothiazide (HCTZ) combined with an epithelial sodium channel (ENaC) inhibitor on coronary mortality and sudden cardiac death.
Searching
PubMed (from 1985) , Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 2, 2006) and related reviews on the consequences of treating hypertension were searched.
Study selection
Randomised controlled trials (RCTs) that compared the effects of diuretic-based antihypertensive treatment (of at least one year) with placebo (or usual care) on coronary mortality or sudden cardiac death were eligible for inclusion. Trials that used concomitant interventions that could potentially confound the effects of thiazides were excluded. For ENaC inhibitor/hydrochlorothiazide combination therapy, eligible trials were those in which the protocols specified that an ENaC inhibitor was to be used routinely in combination with a thiazide diuretic (those that did not meet this criterion were considered as trials that did not mandate use of potassium-sparing diuretics).
ENaC inhibitors administered were triamterene and amiloride. The daily dose of hydrochlorothiazide was 25mg. Thiazide doses in trials that did not mandate use of a potassium-sparing drug ranged from 12.5mg to 50mg daily. Included studies enrolled elderly patients: the mean age of patients in trials that mandated use of an ENaC inhibitor in combination with a thiazide ranged from 70 to 76 years; the mean aged of patients in trials that did not mandate use of a potassium-sparing drug ranged from 38 to 84 years. 
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